Healthcare and tech funds lead October returns as bubble fears grow

Healthcare and tech funds were the clear winners in a month of fresh all-time highs for several major indices

1–2m

Healthcare and tech funds were the clear winners in a month of fresh all-time highs and bubble fears for equity markets.

The FTSE, Nasdaq, S&P, Nikkei, Dax, CAC 40 and the Korean Kospi hit highs in October, leading investors to ponder whether equity markets could be in an AI-driven bubble.

“Everyone seems to be warning of bubbles with the IMF now joining the fray and comparisons to the dotcom period are rife,” said Ben Yearsley, director at Fairview Investing.

“Valuations are much higher now, but so are the profits and cashflow of the main protagonists. I have no idea whether this is truly a bubble in AI, but prudence would suggest not having all your investments pointing in the same direction.”

See also: IBT’s Craig: Choosing biotech fund management over working in a lab is extremely rewarding

The average IA Healthcare sector fund returned 8.25% in October, ahead of Technology & Technology Innovation at 7.93%.

Global Emerging Markets, Asia Pacific ex Japan, and India/Indian Subcontinent also enjoyed strong months.

“Sectors such as biotech have been ignored since the Covid years,” said Yearsley.

“The flurry of deals in the last few months has reignited interest and has highlighted the value on offer. With big pharma on the edge of a huge patent cliff and with cash to spend it feels like the outlook is good and it’s not linked to AI.”

Two Korea-focused strategies led returns for individual funds, with Barings Korea and JPM Korea Equity returning 20.53% and 20.13% respectively.

Elsewhere, wobbles in US regional banks weighed on the Financials & Financial Innovation sector, which was the only fund sector to record negative returns in October.

The foot of the table felt fund-specific rather than sectors driving poor performance, Yearsley added, as China, Japan, gold, and property funds all featured.

Funds – One month (top ten)Return %
Barings Korea+20.53
JPM Korea Equity+20.13
Macquarie Emerging Markets+16.55
Polar Capital Global Technology+14.04
Pictet Biotech+14.02
Polar Capital Biotechnology+13.68
Janus Henderson Global Life Sciences+13.22
Axa Framlington Biotech+13.19
Candriam Biotechnology+12.93
Heptagon Driehaus US Micro Cap Equity+12.77
Source: FE fundinfo, 30 September to 31 October